Market capitalization | $17.02m |
Enterprise Value | $2.20m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.24 |
P/S ratio (TTM) P/S ratio | 1.82 |
P/B ratio (TTM) P/B ratio | 1.24 |
Revenue growth (TTM) Revenue growth | -17.77% |
Revenue (TTM) Revenue | $9.35m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Guardion Health Sciences, Inc.:
1 Analyst has issued a forecast Guardion Health Sciences, Inc.:
Jun '24 |
+/-
%
|
||
Revenue | 9.35 9.35 |
18%
18%
|
|
Gross Profit | 4.02 4.02 |
6%
6%
|
|
EBITDA | -3.83 -3.83 |
21%
21%
|
EBIT (Operating Income) EBIT | -3.85 -3.85 |
30%
30%
|
Net Profit | -5.88 -5.88 |
48%
48%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Guardion Health Sciences, Inc. engages in the provision of health care services. It offers medical food involving the ocular health space. The firm also develops medical devices that measures macular pigment density. The company was founded by Michael Favish in 2009 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Jan Hall |
Employees | 9 |
Founded | 2009 |
Website | www.guardionhealth.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.